The Emerging Innovative Pharmaceutical Enterprises in China
Building on the China Pharmaceutical Innovation and Invention Index, which assesses the overall innovation strength of leading Chinese pharmaceutical companies, here […]
Blog
Revitalizing Pharma Collaborations: The Reblozyl Case Study
In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the
Don’t Let Your Tracker Get Stale: An Interview with Lucy Robin
Don’t Let Your Tracker Get Stale: An Interview with Lucy Robin By The Fulcrum Research Division Lucy Robin is one
Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan
In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about
Decision Frameworks in Pharma: From RAVE and DICE to Lilly’s Truth-Seeking Machine
What Works, What Kills What, and Why It Matters By Mike Rea In pharmaceutical R&D, where billions ride on the
Minimizing Bias in Market Research: An Interview with Erik Coats
Minimizing Bias in Market Research: An Interview with Erik Coats By The Fulcrum Research Division Erik Coats is one of
Challenges and Concerns Raised by EFPIA on Joint Clinical Assessments
In the healthcare regulation sphere, proposed EU-level joint clinical assessments (JCAs) have sparked debate in the pharmaceutical industry. A recent EFPIA report highlights concerns about the rigidity of the guidelines, particularly in oncology, and suggests revisions to ensure a more efficient and adaptable evaluation process that accommodates diverse stakeholder needs across Europe.
Joint Clinical Assessment (EU HTA) Explained
A Comprehensive Exploration of Competitive Intelligence, Knowledge-Sharing, and Strategic Optimization in the Evolving Landscape of EU Health Technology Assessments. The
Rare Disease Day: Uniting Compassion, Data, and Global Action for Accessible Healthcare
What rare disease day means for our work at SAI Every leap year, on the 29th of February, the world
SAI MedPartners Expands Strategic Investments: Driving Growth and Elevating Consultancy Excellence
In the dynamic world of pharmaceutical services, strategic investments play a vital role in shaping the future of organizations. We are happy to announce that we have recently made headlines with our strategic acquisitions of Fulcrum Research Group (FRG) and Pharmaforce International (PFI). To shed light on the motivations behind these investments and the vision driving SAI MedPartners forward, we had the privilege of sitting down with the company’s CEO, Erik Nordhoy.